Added to YB: 2026-07-15
Pitch date: 2026-07-13
NGEN [neutral]
NervGen Pharma Corp.
-10.77%
current return
Author Info
Company Info
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.
Market Cap
$289.8M
Pitch Price
$1.95
Price Target
N/A
Dividend
N/A
EV/EBITDA
-10.30
P/E
-4.31
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
NervGen's Future.
NGEN (update): Thesis reframes NervGen from single peptide NVG-291 (35-amino-acid axonal regrowth) to a 'nervous system ontology' platform—mapping nervous systems + AI to target specific functional restoration (hands, bowel, sexual fn) patients actually pay for. Lower-bar, monetizable outcomes derisk path to cash flow. Long-term: expand beyond peptides to epigenetics/gene editing; pursue foreign approvals first. Highly speculative, conceptual.
Read full article (5 min)